SSRI-induced sexual dysfunction : Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
The authors analyzed the incidence of sexual dysfunction (SD) with different selective serotonin reuptake inhibitors (SSRIs ; fluoxetine, fluvoxamine, paroxetine, and sertraline) and hence the qualitative and quantitative changes in SD throughout time in a prospective and multicenter study.
Outpatients (192 women and 152 men ; age=39.6±11.4 years) under treatment with SSRIs were interviewed with an SD questionnaire designed for this purpose by the authors and that included questions about the following : decreased libido, delayed orgasm or anorgasmia, delayed ejaculation, inability to ejaculate, impotence, and general sexual satisfaction.
Patients with the following criteria were included : normal sexual function before SSRI intake, exclusive treatment with SSRIs or treatment associated with benzodiazepines, previous heterosexual or self-erotic current sexual practices.
Excluded were patients with previous sexual dysfunction, association of SSRIs with neuroleptics, recent hormone intake, and significant medical illnesses.
There was a significant increase in the incidence of SD when physicians asked the patients direct questions (58%) versus when SD was spontaneously reported (14%). There were some significant differences among different SSRIs : paroxetine provoked more delay of orgasm or ejaculation and more impotence than fluvoxamine, fluoxetine and sertraline (X2, p<. 05).
Only 24.5% of the patients had a good tolerance of their sexual dysfunction. (...)
Mots-clés Pascal : Fluoxétine, Paroxétine, Sertraline, Fluvoxamine, Incidence, Epidémiologie, Toxicité, Chimiothérapie, Traitement, Trouble comportement sexuel, Etude multicentrique, Sexe, Homme, Antidépresseur, Psychotrope, Inhibiteur recapture, Sérotonine
Mots-clés Pascal anglais : Fluoxetine, Paroxetine, Sertraline, Fluvoxamine, Incidence, Epidemiology, Toxicity, Chemotherapy, Treatment, Sexual behavior disorder, Multicenter study, Sex, Human, Antidepressant agent, Psychotropic, Reuptake inhibitor, Serotonin
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0468789
Code Inist : 002B02U06. Création : 03/02/1998.